VCAM1 and endothelial dysfunction: Here, we examined whether treatment with ET-1 antagonists BQ123/BQ788 or insulin (1 mU/mL and 10 mU/mL doses (Supplementary Figure S1) can reduce markers associated with endothelial dysfunction ET-1, VCAM1 and ICAM1.